SCHEMBL3009876

SCHEMBL3009876

CNC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 8/20 0.71
HSD17B2 P37059 6/20 0.71
CYP1A2 P05177 3/20 0.71
CYP3A4 P08684 3/20 0.71
CYP2C9 P11712 3/20 0.71
CYP2C19 P33261 3/20 0.71
CYP2D6 P10635 2/20 0.71
MTNR1A P48039 2/20 0.45
MTNR1B P49286 2/20 0.45
PLAU P00749 3/20 0.44
PLG P00747 1/20 0.44
PLAT P00750 1/20 0.44
ERN1 O75460 1/20 0.43
BACE1 P56817 1/20 0.42
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009881 1.00 HSD17B1 (0.71) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3010153 0.88 HSD17B1 (0.75) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3010148 0.88 HSD17B1 (0.75) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3015301 0.88 HSD17B1 (0.66) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3015305 0.88 HSD17B1 (0.66) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3007568 0.83 HSD17B1 (1.00) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3007572 0.83 HSD17B1 (1.00) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3004257 0.80 HSD17B1 (0.64) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3015172 0.78 HSD17B1 (0.67) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9
SCHEMBL3016593 0.75 HSD17B1 (0.51) HSD17B1HSD17B2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
WO-2008116920-A2 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES Universität des Saarlandes (DE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases HSD17B1, HSD17B11, HSD17B2 HSD17B1 1/4885HSD17B2 3/4885CYP1A2 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.